Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. BioInvent International AB (publ)
  6. Summary
    BINV   SE0015244520

BIOINVENT INTERNATIONAL AB (PUBL)

(BINV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
43.24(c) 41.6(c) 43.4(c) 45.4(c) 42.76(c) Last
66 382 57 547 87 082 82 114 106 466 Volume
-2.04% -3.79% +4.33% +4.61% -5.81% Change
More quotes
Estimated financial data (e)
Sales 2021 121 M 13,2 M 13,2 M
Net income 2021 -325 M -35,5 M -35,5 M
Net cash position 2021 1 336 M 146 M 146 M
P/E ratio 2021 -7,06x
Yield 2021 -
Sales 2022 134 M 14,6 M 14,6 M
Net income 2022 -394 M -43,0 M -43,0 M
Net cash position 2022 1 900 M 208 M 208 M
P/E ratio 2022 -9,00x
Yield 2022 -
Capitalization 2 500 M 275 M 273 M
EV / Sales 2021 9,66x
EV / Sales 2022 4,48x
Nbr of Employees 85
Free-Float 89,8%
More Financials
Company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has... 
More about the company
Ratings of BioInvent International AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOINVENT INTERNATIONAL AB (PUBL)
11/25Nomination Committee appointed for BioInvent International's Annual General Meeting 202..
AQ
11/25BioInvent International AB Appoints Nomination Committee for the Annual General Meeting..
CI
11/23BioInvent International
AQ
11/23BioInvent Hosting Key Opinion Leader Webinar on BI-1206
AQ
11/12BIOSTOCK :  BioInvent's CMO on new positive data with BI-1206
AQ
11/09BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral a..
AQ
11/08CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On B..
AQ
11/05CASI Pharmaceuticals Partner and BioInvent International AB Presents Further Positive C..
CI
11/04(R) BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
PU
11/04BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
AQ
11/03BIOSTOCK :  BioInvent offers guidance on upcoming milestones
AQ
10/2828/10/2021 BioInvent Interim Report, January 1 - September 30, 2021
PU
10/28(R) BioInvent International AB Interim report January - September 2021
PU
10/28Invitation to presentation of BioInvent's interim report January–September 2021
AQ
10/28BioInvent International AB Interim report January - September 2021
AQ
More news
News in other languages on BIOINVENT INTERNATIONAL AB (PUBL)
2020HBM Healthcare steigert Gewinn im ersten Quartal markant
2019BIOTECH TIME : Nanobiotix fixe son agenda, Transgène et BioInvent vont plus loin
More news
Chart BIOINVENT INTERNATIONAL AB (PUBL)
Duration : Period :
BioInvent International AB (publ) Technical Analysis Chart | BINV | SE0015244520 | MarketScreener
Technical analysis trends BIOINVENT INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 42,76 SEK
Average target price 115,00 SEK
Spread / Average Target 169%
EPS Revisions
Managers and Directors
Martin Welschof Chief Executive Officer
Stefan Ericsson Chief Financial Officer
Leonard Kruimer Chairman
Björn Frendéus Chief Scientific Officer
Andres McAllister Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOINVENT INTERNATIONAL AB (PUBL)-6.84%275
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678